文献速递慢阻肺

衰老细胞治疗:慢阻肺治疗的新视野

Senotherapy: A New Horizon for COPD Therapy.
PubMed 文献 · Chest · 2020-02-10

本综述指出慢阻肺是肺加速衰老性疾病,衰老细胞积累并分泌SASP模拟慢阻肺炎症介质谱。文章讨论了靶向细胞衰老的衰老细胞治疗药物,包括雷帕霉素、二甲双胍、线粒体靶向抗氧化剂、sirtuin激活剂、miR-34a抑制剂及衰老细胞裂解剂,认为联合衰老细胞裂解剂与衰老抑制剂可能是慢阻肺有价值的新策略,尤其在疾病早期开始。

要点

  • 慢阻肺被视为肺加速衰老性疾病,衰老细胞积累和SASP是核心机制。
  • PI3K/mTOR通路是衰老主要通路,雷帕霉素和二甲双胍可靶向该通路。
  • 联合衰老细胞裂解剂与衰老抑制剂或成慢阻肺新策略,早期开始更佳。

核心结论

  • 靶向细胞衰老的衰老细胞治疗可能成为预防慢阻肺疾病进展和死亡的有前景方法。
  • 联合衰老细胞裂解剂与衰老抑制剂可能是慢阻肺有价值的新方法,尤其在疾病早期开始。
  • 慢阻肺共病共享相同衰老通路且可能通过细胞外囊泡传播,未来单一治疗覆盖多种疾病可行。

研究设计与样本

  • 综述,讨论靶向细胞衰老的新型药物(衰老细胞治疗)及其在慢阻肺中的治疗潜力。

主要发现

  • 慢阻肺中衰老细胞积累并分泌SASP,模拟慢阻肺炎症介质谱。
  • PI3K/mTOR信号激活是衰老主要通路,雷帕霉素和二甲双胍靶向该通路。
  • 线粒体氧化应激是该通路关键驱动机制,线粒体靶向抗氧化剂有前景。
  • 慢阻肺中sirtuin-1和sirtuin-6等抗衰老分子减少,由PI3K/mTOR信号通过miR-34a介导。
  • 衰老细胞裂解剂在衰老动物模型和其他年龄相关疾病初步临床研究中诱导衰老细胞凋亡并减少SASP。

关键数值与推荐

  • PI3K/mTOR通路激活是衰老主要通路,雷帕霉素和二甲双胍靶向该通路。
  • sirtuin-1和sirtuin-6在慢阻肺中减少,由PI3K/mTOR信号通过miR-34a介导。
  • 抑制miR-34a在慢阻肺细胞实验中恢复sirtuin表达。
  • 衰老细胞裂解剂在衰老动物模型和其他年龄相关疾病初步临床研究中减少SASP反应。

临床怎么用

  • 关注靶向PI3K/mTOR通路的现有药物(雷帕霉素、二甲双胍)在慢阻肺中的潜在应用。
  • 线粒体靶向抗氧化剂、sirtuin激活剂和miR-34a抑制剂是待开发方向。
  • 衰老细胞治疗宜早期开始,联合衰老细胞裂解剂与衰老抑制剂可能更有效。

局限性

  • sirtuin激活剂仍在开发中,miR-34a抑制恢复sirtuin表达仅为实验性慢阻肺细胞证据。
  • 衰老细胞裂解剂证据来自衰老动物模型和其他年龄相关疾病初步临床研究,非慢阻肺临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is increasing evidence that COPD is a disease of accelerated lung aging, with the accumulation of senescent cells that lose their ability to repair and secrete multiple inflammatory proteins known as the senescence-associated secretory phenotype (SASP), which mimic the profile of inflammatory mediators secreted in COPD. This review discusses novel drugs (senotherapies) that target cellular senescence and which may be a promising therapeutic approach to prevent currently unaddressed disease progression and mortality in COPD. A major pathway leading to senescence is via the activation of phosphoinositide-3-kinase/mammalian target of rapamycin signaling. Existing drugs, such as rapamycin and metformin, target this pathway. Mitochondrial oxidative stress is a key driving mechanism for this pathway, and mitochondria-targeted antioxidants are promising. A key finding in COPD is loss of antiaging molecules such as sirtuin-1 and sirtuin-6, which are reduced by phosphoinositide-3-kinase/mammalian target of rapamycin signaling through microRNA-34a. Sirtuin activators are in development, and inhibiting microRNA-34a restores sirtuin expression experimentally in COPD cells. Senolytic therapies induce apoptosis and removal of senescent cells and reduce the senescence-associated secretory phenotype response in animal models of aging and in pilot clinical studies of other age-related diseases. A combination of senolytics and senostatics (drugs that inhibit cellular senescence) may be a valuable new approach to COPD, especially if started early in the disease process. Furthermore, COPD is associated with several comorbidities that share the same aging pathways which may be spread by extracellular vesicles, and thus a single treatment for all these diseases is feasible in the future to extend health span.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Baker JR, Donnelly LE, Barnes PJ, et al. Senotherapy: A New Horizon for COPD Therapy. Chest. 2020. PMID: 32057805. doi:10.1016/j.chest.2020.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。